Opioid Withdrawal Treatment Market

The global Opioid Withdrawal Treatment market size was USD 1.13 billion in 2023 and is calculated at USD 1.24 Billion in 2024. The market is projected to reach USD 3.26 Billion in 2034 and register a revenue 10. 1% over the forecast period (2025-2034).

Premium Insights:

Growth of the Opioid Withdrawal Treatment market has increased significantly over the past decade due to increasing prevalence of Opioid Use Disorder (OUD), and addiction and opioid dependence, and individuals voluntarily or involuntarily opting to towards stability and eventual abstinence from opioids altogether. Attempts to stop use of opioids causes Opioid Withdrawal Syndrome or OWS, which creates need for subsequent and appropriate treatment and medications to alleviate withdrawal symptoms and diminish cravings, and management strategies and solutions to aid further to total recovery.

Also, rising awareness among the public as well as increasing number of government and public-private initiatives aimed at curbing the opioid crisis have been leading to implementation of policies that support Medication-Assisted Treatments (MAT) for opioid withdrawal. As a result of supportive MAT policies, the availability of treatments such as methadone, buprenorphine, and naltrexone, which are currently more accessible across different healthcare settings has enabled wider accessibility and is also encouraging more individuals to opt for ways of dealing with opioid dependence and disorders.

Demand for Opioid Withdrawal Treatment programs is also rising due to these being designed to manage specific challenges as well as cater to needs of patients during the withdrawal process, address symptoms and behaviors, and provide support on the road to recovery. While Opioid Use Disorder (OUD) treatment is centered on enduring control and recovery from opioid addiction, Opioid Withdrawal Treatment is designed to aid the individuals with immediate opioid withdrawal symptoms emerging due to weaning off opioids, reducing use or dosage, or stopping use altogether on the recovery path. Proper and efficient approaches, treatments, and strategies are crucial to successful managing and handling individuals with OWS, and this is also important in OUD treatment. Among the various stages of treatment, the detoxification stage and severe withdrawal symptom this brings along, continues to prove most challenging for care providers and patients alike.

In addition, advancements in healthcare infrastructure, reducing stigma associated with Opioid Withdrawal Treatments, better understanding of opioid addiction as a medical condition, and increasing number of individuals seeking Opioid Withdrawal Treatment has been supporting inclining adoption of these therapies and treatment approaches. The outcomes have also been positive and favorable, and these are some of the key factors expected to continue to have major and positive impact on growth of the global Opioid Withdrawal Treatment market.

Some opioids are frequently prescribed for medical use, particularly for pain management or opioid dependence treatment. Natural and semi-synthetic opioids include morphine, which is often prescribed for severe pain, particularly after surgery or for cancer-related pain, codeine for mild to moderate pain and also used in some cough syrups; Oxycodone (OxyContin, Percocet) is commonly prescribed for moderate to severe pain, often in combination with acetaminophen or other medications; Hydrocodone (Vicodin, Lortab) is used to treat moderate to severe pain, frequently combined with acetaminophen; Hydromorphone (Dilaudid), which is a more potent opioid, prescribed for severe pain; Heroin – though not prescribed medically, it is a semi-synthetic opioid derived from morphine, used illicitly.

Synthetic opioids include Fentanyl, which is used for severe pain, particularly in cancer patients. It can also be found in patches or lozenges. Methadone is used for both pain relief and as part of medication-assisted treatment (MAT) for opioid addiction. Buprenorphine (Suboxone, Subutex) is a partial opioid agonist, used in treating opioid dependence as part of MAT. Tramadol (Ultram) is used for moderate to moderately severe pain, though it is not considered a weaker opioid. Meperidine (Demerol) was previously popular for pain relief, but is now less commonly used due to its side effects.

Less common or discontinued opioids include Propoxyphene, which was previously used for pain relief, but was removed from the market due to safety concerns. LAAM (L-alpha-acetylmethadol) is used to treat opioid dependence, though it is rarely prescribed today.

As the opioid epidemic continues to escalate, there is a growing demand for comprehensive withdrawal treatment options that address both, acute symptoms of withdrawal and the underlying addiction. This has been prompting pharmaceutical companies and healthcare providers to develop and expand treatment modalities tailored to manage opioid withdrawal more effectively and address urgent needs of individuals seeking to combat dependence on opioids as well as persons with OUD and OWS seeking help.

Opioid Withdrawal Treatment involves managing symptoms that arise when discontinuing opioid use. This treatment typically includes medications such as methadone, buprenorphine, and naltrexone, which help reduce cravings and withdrawal symptoms. Administering of nonsteroidal anti-inflammatory drugs, anti-nausea medications, analgesics, natural sleep supplements, behavioral therapies, and support programs are also integral in aiding patient recovery. Advancements in medication formulations, including extended-release versions, which improve patient compliance and outcomes have been having a positive impact on patient outcomes. Digital health technologies like telemedicine and mobile apps are also becoming reliable tools for providing remote care and monitoring to individuals.

Some key trends in the market include increasing adoption of non-opioid therapies, personalized treatment plans, and integration of Artificial Intelligence (AI) for predictive analytics in patient care. Companies are focusing on research and development to discover novel therapeutic approaches and innovation to enhance existing treatments.

Top Opioid Withdrawal Treatment Market Drivers and Trends:

Increasing Prevalence of Opioid Addiction and Dependence: Prevalence of opioid addiction and dependence has been increasing worldwide and in some countries is considered an opioid epidemic. Governments and healthcare organizations are focusing on prioritizing withdrawal treatments and patient management strategies to aid in decreasing addiction and combating dependence on opioids. Such initiatives are also driving steady shift towards non-opioid treatments for pain and other conditions and diseases, and this is resulting in substantial increase in investments towards various alternative routes and approaches to address this growing crisis. A number of awareness drives regarding opioid withdrawal symptoms and potential risks and adverse consequences and also initiatives to encourage individuals to seek treatment across various healthcare settings such as hospitals, rehabilitation centers, and outpatient facilities has been having a positive impact on market growth.

Technological Advancements in Withdrawal Treatment: Technological advancements are playing a major role in addressing challenges in withdrawal treatment. This is supporting innovations in Medication-Assisted Treatment (MAT) and enabling development of long-acting formulations such as buprenorphine, naltrexone, and methadone, to provide more effective, controlled, and easier-to-administer solutions for patients with OWS. Also, integration of digital health tools and telemedicine platforms are expanding access to treatment, particularly for individuals in rural or underserved areas.

R&D Funding and Targeted Therapies: Increasing funding and research and development initiatives are aiding in designing and formulation of more sophisticated and targeted therapies, and companies are focusing intently on development of treatments that are safe and more effective than some existing on the market currently. Pharmaceutical companies are also adopting product strategies aimed at improving patient compliance and reducing side effects, and such initiatives, with the appropriate funding and relevant support are expected to have a positive impact on growth of the Opioid Withdrawal Treatment market.

Destigmatization of OUD and Understanding Opioid Addiction: The steady destigmatization of Opioid Use Disorder (OUD) treatment and rising support for evidence-based practices are supporting inclining acceptance for various treatments. Promotion of MAT as the gold standard for opioid withdrawal management by healthcare organizations and increasing number of healthcare providers and facilities integrating these treatments and therapies into routine care are major factors expected to support growth of the market. Various trends such as public and private partnerships to address issues related to opioid addiction and dependence, as well as to encourage and provide support to individuals seeking treatment and management strategies to cope with the crisis along with supporting government and non-government organization funding and incentives are expected to continue to drive market revenue growth over the forecast period.

Opioid Withdrawal Treatment Market Restraining Factor Insights:

High Treatment Costs: High cost of treatment, specifically for advanced medication-assisted therapies like buprenorphine or naltrexone, can have a negative impact on preferences among some individuals. Also, this is a major restraint for patients or individuals lacking adequate insurance coverage and for those without access to government-supported programs. Moreover, treatment and therapies can extend over long periods during recovery, and this can add up to financial burden.

Social Barriers and Stigma Related to OUD Treatment: Though stigma and social barriers surrounding opioid use disorder treatment have been easing, some individuals may still be reluctant to seek help due to apprehension and potential profiling by peers or public. Some individuals may also avoid opting for treatment due to fear of being judged, being misunderstood, or being ostracized from circles. These factors also have a negative impact on the healthcare system, with some providers and facilities not including cover or providing adequate treatment due to low demand in certain cities or regions.

Side effects and Potential Substitute Addiction: Medications used for opioid withdrawal, such as methadone and buprenorphine, help manage withdrawal symptoms, but can themselves be addictive and create dependency if improperly and frequently administered. Possibility of substituting one addiction for another can create some level of fear and hesitation, and preference for these drugs is limited among some healthcare providers and patients.

Research and Development Challenges: Developing novel treatments with fewer side effects or more efficient mechanisms of action is time-consuming and costly. Regulatory approval processes can be lengthy, and pharmaceutical companies may be hesitant to invest majorly in Opioid Withdrawal Treatments due to uncertainties in Returns on Investment (RoI).

Policy Changes and Restrictive Regulations: Policies and regulations related to the distribution and prescribing of Opioid Withdrawal Treatment and medications could have a negative impact on market growth. Stringent prescribing guidelines or limitations on MAT availability can restrain market growth, as more controlled access to these treatments can lead to reduced adoption rates, even in places where treatment is needed most.

Opioid Withdrawal Treatment Market Opportunities:

Expanding Into Emerging Markets: Rising opioid dependence and increasing number of individuals understanding the risks and dangers of addiction as well as the challenges of stopping opioid usage presents lucrative opportunities for companies operating in the Opioid Withdrawal Treatment market. Companies can focus on regions and markets where awareness regarding the various risks and challenges associated with opioid dependence is rising and also cater to needs of niche segments of withdrawal from other substances. Opportunities are also present in regions where awareness and access to treatment are limited, and strategic partnerships with local healthcare providers or governments could facilitate wider reach and expansion, and create new revenue streams.

R&D Investment for innovative treatment options and delivery: Companies can also focus on investments into R&D to develop innovative treatment options and delivery systems. Development of new formulations of opioid withdrawal medications with fewer side effects or longer-lasting effects can enable product differentiation in an increasingly competitive market.

Mergers, Acquisitions, and Collaborations: Entering into mergers, acquisitions, and collaborations with pharmaceutical or biotech companies can open growth avenues and opportunity for diversification. Expanding portfolios through acquisition of innovative start-ups or entering Joint Ventures (JVs) that specialize in digital health or telemedicine platforms can enable leveraging trends that increasingly being integrated into opioid treatment. These collaborations can help companies stay at the forefront of the market by leveraging technological advancements and tapping into new distribution channels.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Opioid Withdrawal Treatment Market Segmentation:

By Treatment Type:

• Medication-Assisted Treatment (MAT)
• Non-Medication-Based Therapy
• Detoxification Treatment
• Behavioral Therapy

By Drug Type:

• Buprenorphine
• Methadone
• Naltrexone
• Clonidine
• Lofexidine

By End-User:

• Hospitals & Clinics
• Rehabilitation Centers
• Homecare Settings
• Specialty Treatment Centers

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Treatment Programs (Government and Private)

Segment Insights:

By Treatment Type:

The Medication-Assisted Treatment (MAT) segment is expected to account for largest revenue share among the treatment type segments in the global Opioid Withdrawal Treatment market over the forecast period. Combination in MAT of FDA-approved medications such as buprenorphine, methadone, and naltrexone with behavioral therapies to treat opioid use disorder is highly effective in reducing withdrawal symptoms and cravings, which significantly improves patient compliance and outcomes. High and rising preference for this treatment is supported by strong clinical evidence exhibiting ability of MAT to decrease opioid overdose deaths and long-term opioid dependence. MAT is also being recommended by government and healthcare organizations as the standard for treating OUD, which is further supporting revenue growth of this segment.

By Drug Type:

Among drug type segments, the buprenorphine segment is expected to account for largest revenue share. Buprenorphine is a partial opioid agonist, offering benefits of reducing cravings and opioid withdrawal symptoms without the high risk of overdose or abuse associated with other opioids. Also, long-acting formulations of buprenorphine, such as extended-release injections, have also gained popularity due to their convenience and ability to reduce the need for daily administration. With more physicians certified to prescribe buprenorphine and its growing use in outpatient settings, this drug has become a cornerstone of MAT for Opioid Withdrawal Treatment, and these factors are expected to continue to contribute to revenue growth of this segment.

By End-User:

The hospitals and clinics segment is expected to account for largest revenue among end-user segments over the forecast period. Hospitals and clinics are the primary healthcare settings for initiating Opioid Withdrawal Treatments, particularly for severe cases requiring close medical supervision and supporting treatments and care. Hospitals and clinics are also equipped to provide both MAT and detoxification treatments, along with comprehensive care that includes monitoring, counseling, and support services. Increasing integration of MAT in hospitals to strengthen opioid treatment programs, rising demand for opioid withdrawal medications and services in these settings, and hospital-based programs being supported by government funding and insurance coverage are other key factors driving revenue growth of this segment.

By Distribution Channel:

Among distribution channel segments, the hospital pharmacies segment is expected to account for largest revenue share. Hospital pharmacies are a key distribution point for opioid withdrawal medications, especially for inpatients undergoing MAT or detoxification. The controlled environment of hospital pharmacies ensures that medications like methadone and buprenorphine are administered under strict supervision, thereby reducing the risk of misuse or diversion. Also, hospital pharmacies benefit from partnerships with healthcare providers and insurance companies, ensuring consistent demand for Opioid Withdrawal Treatment.

Regions and Countries

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India

Rest of Asia Pacific

• Latin America
• Brazil
• Argentina

Rest of Latin America

• Middle East & Africa
• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA

Opioid Withdrawal Treatment Market Regional Landscape:

Among the regional markets, North America is the leading regional market, driven primarily by the US, which accounts for largest revenue, and Canada also dealing with an opioid crisis. Factors such as high prevalence of opioid addiction and overdose deaths, robust presence of Opioid Withdrawal Treatment programs, and high adoption rate of medication-assisted treatment to address needs of a rapidly expanding patient population seeking treatments and care for opioid withdrawal symptoms are driving growth of the market in the region.

In Europe, the United Kingdom and Germany are key markets for Opioid Withdrawal Treatment, and rising adoption rates are driven by robust healthcare systems and government support for addiction treatment services. Also, increasing opioid dependence in parts of Europe, particularly due to prescription opioids, is supporting the demand for these treatments and programs.

In Asia Pacific, China and India are emerging markets due to rising opioid abuse and greater awareness of addiction treatment options. As healthcare infrastructure improves and investment in healthcare facilities increase, demand for more comprehensive Opioid Withdrawal Treatments is expected to rise significantly in these countries.

Latin America is also registering rising demand for Opioid Withdrawal Treatment and adoption of associated programs. Addiction rates are relatively high in Brazil and Mexico, and favorable government initiatives and funding and rising awareness regarding these solutions are key factors expected to support growth of the market in the region.

Opioid Withdrawal Treatment Market Competitive Landscape:

Company List:

• Indivior PLC
• Alkermes PLC
• BioDelivery Sciences International, Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer, Inc.
• Mallinckrodt Pharmaceuticals
• Orexo AB
• Hikma Pharmaceuticals
• Viatris Inc. (formerly Mylan)
• Purdue Pharma L.P.

The global Opioid Withdrawal Treatment market is competitive, with a number of leading companies making strategic moves to maintain and expand their market position. Some key strategies include mergers and acquisitions, partnerships, product innovations, and global footprint expansion. Companies such as Alkermes, Teva Pharmaceuticals, Indivior, and Mallinckrodt Pharmaceuticals are focusing on expanding their product portfolios and conducting extensive research and development to introduce new, more effective treatments for opioid withdrawal. Mergers and acquisitions are a common strategy to strengthen market presence and diversify offerings, and companies such as Mylan (now part of Viatris) and BioDelivery Sciences have actively pursued strategic mergers to broaden their product lines. In addition, companies like Orexo AB and Indivior have concentrated on improving the efficacy of their treatments, with a focus on non-opioid therapies to reduce dependency risks and enhance patient outcomes.

Another key strategy involves geographic expansion, particularly in emerging markets where opioid use is rising, and treatment demand is increasing. Expanding availability of Opioid Withdrawal Treatments in developing regions and collaborations with healthcare providers and governments to improve access to affordable treatment options are other strategies observed in the market.

Recent Developments

• November 6, 2023: BioXcel Therapeutics, Inc., which is a biopharmaceutical company utilizing Artificial Intelligence (AI) to develop transformative medicines in neuroscience, announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for Opioid Use Disorder (OUD). According to the announcement, dexmedetomidine has potential to treat patients who are physically dependent on illicit and prescription opioids, and is believed to be particularly helpful in treating withdrawal symptoms in patients who are dependent on fentanyl and/or fentanyl adulterated with xylazine.
• May 23, 2023: The US Food and Drug Administration (FDA) approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). The two formulations Brixadi is available in are a weekly injection for those patients who began treatment with a single dose of a transmucosal buprenorphine product or who are being treated with buprenorphine, and a monthly injection for patients already being treated with buprenorphine.

Frequently Asked Questions:

Q: What is the global Opioid Withdrawal Treatment market size in 2023 and what is the projection for 2034?

A: The global Opioid Withdrawal Treatment market size was USD 1.13 billion in 2023 and expected to reach USD 3.26 billion in 2034.

Which regional market accounted for largest revenue share in 2023, and what is the expected trend over the forecast period?

A: North America accounted for largest revenue share in 2023, and is also expected to continue to maintain its lead in terms of growth rate over the forecast period.

Q: Which are the major companies are included in the global Opioid Withdrawal Treatment market report?

A: Major companies in the market report are Indivior PLC, Alkermes PLC, BioDelivery Sciences International, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Mallinckrodt Pharmaceuticals, Orexo AB, Hikma Pharmaceuticals, Viatris Inc. (formerly Mylan), Purdue Pharma L.P.

Q: What is the projected revenue CAGR of the global Opioid Withdrawal Treatment Market over the forecast period?

A: The global Opioid Withdrawal Treatment market is expected to register a CAGR of 10.1% between 2025 and 2034.

Q: What are some key factors driving revenue growth of the Opioid Withdrawal Treatment market?

A: Some key factors driving market revenue growth include rising prevalence of Opioid Use Disorder (OUD), and addiction and opioid dependence, and individuals voluntarily or involuntarily opting to towards stability and eventual abstinence from opioids altogether, increasing number of government and public-private initiatives aimed at curbing the opioid crisis, and implementation of policies that support Medication-Assisted Treatments (MAT) for opioid withdrawal.